These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 29364586)

  • 41. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
    Liu Y; Zhang X; Chai S; Zhao X; Ji L
    J Diabetes Res; 2019; 2019():1534365. PubMed ID: 31396537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
    Urquhart S; Willis S
    JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Dulaglutide and liraglutide compared].
    Bruhn C
    Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
    [No Abstract]   [Full Text] [Related]  

  • 46. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
    Almeida OP; Fong Z; Hill Almeida LM; Sanfilippo FM; Page A; Etherton-Beer C
    Diabetes Obes Metab; 2024 Jul; 26(7):2925-2932. PubMed ID: 38650544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Practical guidance for use of oral semaglutide in primary care: a narrative review.
    Morales J; Shubrook JH; Skolnik N
    Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
    Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
    Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
    Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH
    PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
    Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
    Storgaard H; Cold F; Gluud LL; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2017 Jun; 19(6):906-908. PubMed ID: 28105738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening.
    Varughese GI; Jacob S
    J R Coll Physicians Edinb; 2024 Jun; 54(2):170-173. PubMed ID: 38578067
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.